Iwai N, Suzuki C, Maki T, Tauchi N, Kawamura M
Jpn J Antibiot. 1977 Sep;30(9):710-21.
In order to clinically evaluate S-6437, the following study was carried out in pediatric patients. This clinical study was performed in 30 patients ranging from 2 years and one month to 10 years and one month of age. Seven patients had scarlet fever, 3 acute pharyngitis, 4 acute suppurative tonsillitis, 6 acute bronchitis, 2 acute pneumonia, 3 acute pyelonephritis, 1 chronic pyelonephritis, 2 vaginitis, 1 acute gastro-enteritis, and 1 impetigo. The degree of these diseases were all mild or moderate. These patients were orally administered 35 approximately 50 mg/kg/day in two divided doses for 3 approximately 10 days. As a result, effectiveness of this preparation in these patients was 80% and no side effects were observed.
为了对S - 6437进行临床评估,在儿科患者中开展了以下研究。这项临床研究在30名年龄从2岁1个月至10岁1个月的患者中进行。7名患者患有猩红热,3名患有急性咽炎,4名患有急性化脓性扁桃体炎,6名患有急性支气管炎,2名患有急性肺炎,3名患有急性肾盂肾炎,1名患有慢性肾盂肾炎,2名患有阴道炎,1名患有急性肠胃炎,1名患有脓疱病。这些疾病的程度均为轻度或中度。这些患者口服该制剂,剂量约为50mg/kg/天,分两次服用,持续3至10天。结果,该制剂在这些患者中的有效率为80%,且未观察到副作用。